TY - JOUR
T1 - Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment - Results from 12 countries in EuroSpA
AU - Brahe, Cecilie Heegaard
AU - Ørnbjerg, Lykke Midtbøll
AU - Jacobsson, Lennart
AU - Nissen, Michael J.
AU - Kristianslund, Eirik Klami
AU - Mann, Herman
AU - Santos, Maria José
AU - Reino, Juan G. mez
AU - Nordström, Dan
AU - Rotar, Ziga
AU - Gudbjornsson, Bjorn
AU - Onen, Fatos
AU - Codreanu, Catalin
AU - Lindström, Ulf
AU - Möller, Burkhard
AU - Kvien, Tore K.
AU - Pavelka, Karel
AU - Barcelos, Anabela
AU - Sánchez-Piedra, Carlos
AU - Eklund, Kari K.
AU - Tomšič, Matija
AU - Love, Thorvardur Jon
AU - Can, Gercek
AU - Ionescu, Ruxandra
AU - Loft, Anne Gitte
AU - van der Horst-Bruinsma, I. E.
AU - MacFarlane, Gary J.
AU - Iannone, Florenzo
AU - Hyldstrup, Lise Hejl
AU - Krogh, Niels Steen
AU - Østergaard, Mikkel
AU - Hetland, Merete Lund
PY - 2020/7/1
Y1 - 2020/7/1
N2 - To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naïve patients with PsA. Methods: Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis ≤4] and ACR criteria for 20% improvement (ACR20)/ACR50/ACR70 were calculated, including LUNDEX adjustment. Results: Overall, 14 261 patients with PsA initiated a first TNFi. Considerable heterogeneity of baseline characteristics between registries was observed. The median 12-month retention rate (95% CI) was 77% (76, 78%), ranging from 68 to 90% across registries. Overall, DAS28/28 joint Disease Activity index for Psoriatic Arthritis remission rates at 6 months were 56%/27% (LUNDEX: 45%/22%). Six-month ACR20/50/70 responses were 53%/38%/22%, respectively. In patients initiating a first TNFi after 2009 with registered fulfilment of ClASsification for Psoriatic ARthritis (CASPAR) criteria (n = 1980) or registered one or more swollen joint at baseline (n = 5803), the retention rates and response rates were similar to those found overall. Conclusion: Approximately half of >14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database of PsA patients treated in routine care was demonstrated, offering unique opportunities for research with real-world data.
AB - To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naïve patients with PsA. Methods: Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis ≤4] and ACR criteria for 20% improvement (ACR20)/ACR50/ACR70 were calculated, including LUNDEX adjustment. Results: Overall, 14 261 patients with PsA initiated a first TNFi. Considerable heterogeneity of baseline characteristics between registries was observed. The median 12-month retention rate (95% CI) was 77% (76, 78%), ranging from 68 to 90% across registries. Overall, DAS28/28 joint Disease Activity index for Psoriatic Arthritis remission rates at 6 months were 56%/27% (LUNDEX: 45%/22%). Six-month ACR20/50/70 responses were 53%/38%/22%, respectively. In patients initiating a first TNFi after 2009 with registered fulfilment of ClASsification for Psoriatic ARthritis (CASPAR) criteria (n = 1980) or registered one or more swollen joint at baseline (n = 5803), the retention rates and response rates were similar to those found overall. Conclusion: Approximately half of >14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database of PsA patients treated in routine care was demonstrated, offering unique opportunities for research with real-world data.
KW - DAPSA28
KW - DAS28
KW - TNFi
KW - drug survival
KW - effectiveness
KW - epidemiology
KW - psoriatic arthritis
KW - register
KW - response
KW - spondyloarthritis
UR - http://www.scopus.com/inward/record.url?scp=85084200183&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/rheumatology/kez427
DO - https://doi.org/10.1093/rheumatology/kez427
M3 - Article
C2 - 31665497
SN - 1462-0324
VL - 59
SP - 1640
EP - 1650
JO - Rheumatology (Oxford, England)
JF - Rheumatology (Oxford, England)
IS - 7
ER -